Adenovirus-mediated gene transfer of tissue factor pathway inhibitor-2 inhibits gallbladder carcinoma growth in vitro and in vivo

Cancer Science

Volumn 103, Issue 4, 2012, Pages 723-730

  Qin, Yiyu ^a   Zhang, Shenglai ^a   Gong, Wei ^a   Li, Jiyu ^a   Jia, Jianguang ^a   Quan, Zhiwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYTOCHROME C; PLACENTA PROTEIN 5; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR 2; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; GALLBLADDER CARCINOMA; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GALLBLADDER NEOPLASMS; GENE TRANSFER TECHNIQUES; GENES, SUPPRESSOR; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; MALE; MICE; MURINE PNEUMONIA VIRUS; NEOPLASM TRANSPLANTATION;

EID: 84862817334     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02218.x     Document Type: Article

References (36)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-76.
2. Eslick GD. Epidemiology of gallbladder cancer. Gastroenterol Clin North Am 2010; 39: 307-30, ix.
3. de Aretxabala X, Roa I, Berrios M et al. Chemoradiotherapy in gallbladder cancer. J Surg Oncol 2006; 93: 699-704.
4. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg 2008; 196: 252-64.
5. Saetta A, Lazaris AC, Michalopoulos NV, Davaris PS. Genetic alterations involved in the development of gallbladder carcinomas from Greek patients. Hepatogastroenterology 2001; 48: 1284-8.
6. Kim YT, Kim J, Jang YH et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001; 169: 59-68.
7. Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y. Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 2000; 7: 198-205.
8. Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 2001; 193: 380-3.
9. Puhalla H, Wrba F, Kandioler D et al. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res 2007; 27: 1679-84.
10. Chand HS, Foster DC, Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost 2005; 94: 1122-30.
11. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996; 35: 266-72.
12. Herman MP, Sukhova GK, Kisiel W et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107: 1117-26.
13. Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozlowski L, Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003; 90: 140-6.
14. Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007; 33: 653-9.
15. Wong CM, Ng YL, Lee JM et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007; 45: 1129-38.
16. Sell SM, Tullis C, Strancner D, Song CY, Gewin J. Minimal interval defined on 7q in uterine leiomyoma. Cancer Genet Cytogenet 2005; 157: 67-9.
17. Kempaiah P, Chand HS, Kisiel W. Identification of a human TFPI-2 splice variant that is upregulated in human tumor tissues. Mol Cancer 2007; 6: 20.
18. Ma S, Chan YP, Kwan PS et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res 2011; 71: 583-92.
19. Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 310-6.
20. Hisaka T, Lardeux B, Lamireau T et al. Expression of tissue factor pathway inhibitor-2 in murine and human liver regulation during inflammation. Thromb Haemost 2004; 91: 569-75.
21. Kondraganti S, Gondi CS, Gujrati M et al. Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line. Int J Oncol 2006; 29: 25-32.
22. Kempaiah P, Kisiel W. Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. Apoptosis 2008; 13: 702-15.
23. Tasiou A, Konduri SD, Yanamandra N et al. A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas. Int J Oncol 2001; 19: 591-7.
24. Wang S, Xiao X, Zhou X et al. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010; 10: 617.
25. Müller J, Thirion C, Pfaffl MW. Electric cell-substrate impedance sensing (ECIS) based real-time measurement of titer dependent cytotoxicity induced by adenoviral vectors in an IPI-2I cell culture model. Biosens Bioelectron 2011; 26: 2000-5.
26. Schierack P, Nordhoff M, Pollmann M et al. Characterization of a porcine intestinal epithelial cell line for in vitro studies of microbial pathogenesis in swine. Histochem Cell Biol 2006; 125: 293-305.
27. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
28. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001; 3: E255-63.
29. Ow YP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol 2008; 9: 532-42.
30. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-908.
31. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
32. Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med 2000; 192: 21-6.
33. Zhao B, Luo X, Shi H, Ma D. Tissue factor pathway inhibitor-2 is downregulated by ox-LDL and inhibits ox-LDL induced vascular smooth muscle cells proliferation and migration. Thromb Res 2011; 128: 179-85.
34. Shibuya M, Okamoto H, Nozawa T et al. Proteomic and transcriptomic analyses of retinal pigment epithelial cells exposed to REF-1/TFPI-2. Invest Ophthalmol Vis Sci 2007; 48: 516-21.
35. Shinoda E, Yui Y, Hattori R et al. Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells. J Biol Chem 1999; 274: 5379-84.
36. Jia J, Li S, Gong W, Ding J, Fang C, Quan Z. mda-7/IL-24 induces apoptosis in human GBC-SD gallbladder carcinoma cells via mitochondrial apoptotic pathway. Oncol Rep 2011; 25: 195-201.